IL222012A - Controlled-release dosage forms for high-dose hygroscopic and water-soluble pharmaceuticals - Google Patents
Controlled-release dosage forms for high-dose hygroscopic and water-soluble pharmaceuticalsInfo
- Publication number
- IL222012A IL222012A IL222012A IL22201212A IL222012A IL 222012 A IL222012 A IL 222012A IL 222012 A IL222012 A IL 222012A IL 22201212 A IL22201212 A IL 22201212A IL 222012 A IL222012 A IL 222012A
- Authority
- IL
- Israel
- Prior art keywords
- dosage forms
- water soluble
- controlled release
- high dose
- release dosage
- Prior art date
Links
- 238000013270 controlled release Methods 0.000 title 1
- 239000002552 dosage form Substances 0.000 title 1
- 229940088679 drug related substance Drugs 0.000 title 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
- A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
- A61K9/2846—Poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/2853—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers, poly(lactide-co-glycolide)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
- A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2893—Tablet coating processes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurology (AREA)
- General Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Anesthesiology (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US31721210P | 2010-03-24 | 2010-03-24 | |
| PCT/US2011/029802 WO2011119839A1 (en) | 2010-03-24 | 2011-03-24 | Controlled release dosage forms for high dose, water soluble and hygroscopic drug substances |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL222012A true IL222012A (en) | 2017-11-30 |
Family
ID=44673619
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL222012A IL222012A (en) | 2010-03-24 | 2012-09-20 | Controlled-release dosage forms for high-dose hygroscopic and water-soluble pharmaceuticals |
Country Status (10)
| Country | Link |
|---|---|
| US (9) | US20120076865A1 (enExample) |
| EP (1) | EP2549987A4 (enExample) |
| JP (1) | JP5968300B2 (enExample) |
| CN (1) | CN102917697B (enExample) |
| AU (1) | AU2011232408B2 (enExample) |
| BR (1) | BR112012024019B1 (enExample) |
| CA (1) | CA2794171C (enExample) |
| IL (1) | IL222012A (enExample) |
| MX (2) | MX377251B (enExample) |
| WO (1) | WO2011119839A1 (enExample) |
Cited By (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11400065B2 (en) | 2019-03-01 | 2022-08-02 | Flamel Ireland Limited | Gamma-hydroxybutyrate compositions having improved pharmacokinetics in the fed state |
| US11504347B1 (en) | 2016-07-22 | 2022-11-22 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
| US11583510B1 (en) | 2022-02-07 | 2023-02-21 | Flamel Ireland Limited | Methods of administering gamma hydroxybutyrate formulations after a high-fat meal |
| US11602512B1 (en) | 2016-07-22 | 2023-03-14 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
| US11602513B1 (en) | 2016-07-22 | 2023-03-14 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
| US11779557B1 (en) | 2022-02-07 | 2023-10-10 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
| US11839597B2 (en) | 2016-07-22 | 2023-12-12 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
| US11986451B1 (en) | 2016-07-22 | 2024-05-21 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
| US12186296B1 (en) | 2016-07-22 | 2025-01-07 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
| US12478604B1 (en) | 2016-07-22 | 2025-11-25 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
Families Citing this family (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP5553830B2 (ja) | 2008-07-21 | 2014-07-16 | アルベマール・コーポレーシヨン | 高含量イブプロフェンナトリウム顆粒、その調製、および非発泡性固体剤形を調製する際のその使用 |
| US8771735B2 (en) * | 2008-11-04 | 2014-07-08 | Jazz Pharmaceuticals, Inc. | Immediate release dosage forms of sodium oxybate |
| US8778398B2 (en) * | 2008-11-04 | 2014-07-15 | Jazz Pharmaceuticals, Inc. | Immediate release formulations and dosage forms of gamma-hydroxybutyrate |
| BR112012024019B1 (pt) | 2010-03-24 | 2021-10-19 | Jazz Phamaceuticals, Inc | Forma de dosagem de liberação controlada para administração oral |
| US20160068463A1 (en) | 2012-11-14 | 2016-03-10 | Metabolix, Inc. | Production of salts of 4-hydroxybutyrate using biobased raw materials |
| MX2015007571A (es) * | 2012-12-14 | 2016-04-15 | Si Group Inc | Granulos con alto contenido de ibuprofeno sodico, su preparacion y su uso en la preparacion de formas de dosis solidas no efervescentes. |
| WO2014127053A2 (en) | 2013-02-13 | 2014-08-21 | Metabolix, Inc. | Process for ultra pure chemical production from biobased raw starting materials |
| US9050302B2 (en) | 2013-03-01 | 2015-06-09 | Jazz Pharmaceuticals Ireland Limited | Method of administration of gamma hydroxybutyrate with monocarboxylate transporters |
| US20150275167A1 (en) * | 2014-03-28 | 2015-10-01 | Corning Incorporated | Composition and method for cell culture sustained release |
| PT3131549T (pt) * | 2014-07-09 | 2018-07-04 | Pf Medicament | Método para tratar distúrbios do movimento com befiradol |
| CA2910865C (en) | 2014-07-15 | 2016-11-29 | Isa Odidi | Compositions and methods for reducing overdose |
| US10398662B1 (en) * | 2015-02-18 | 2019-09-03 | Jazz Pharma Ireland Limited | GHB formulation and method for its manufacture |
| FR3049463B1 (fr) * | 2016-04-01 | 2019-07-05 | Debregeas Et Associes Pharma | Doses unitaires a liberation immediate de ghb ou de l'un de ses sels therapeutiquement acceptables administrees par voie orale et leur utilisation pour maintenir l'abstinence alcoolique |
| US11000498B2 (en) | 2016-07-22 | 2021-05-11 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
| US20180263936A1 (en) | 2017-03-17 | 2018-09-20 | Jazz Pharmaceuticals Ireland Limited | Gamma-hydroxybutyrate compositions and their use for the treatment of disorders |
| US11337920B2 (en) | 2017-12-18 | 2022-05-24 | Tris Pharma, Inc. | Pharmaceutical composition comprising GHB gastro-retentive raft forming systems having trigger pulse drug release |
| WO2019126215A1 (en) | 2017-12-18 | 2019-06-27 | Tris Pharma, Inc. | Ghb pharmaceutical compositions comprising a floating interpenetrating polymer network forming system |
| WO2019126218A1 (en) | 2017-12-18 | 2019-06-27 | Tris Pharma, Inc. | Modified release drug powder composition comprising gastro-retentive raft forming systems having trigger pulse drug release |
| CN111511355A (zh) | 2017-12-20 | 2020-08-07 | 弗拉梅爱尔兰有限公司 | 具有改善稳定性的γ-羟基丁酸盐的包装改性释放制剂 |
| MX2021005691A (es) * | 2018-11-19 | 2021-07-07 | Jazz Pharmaceuticals Ireland Ltd | Formulaciones de farmacos resistentes al alcohol. |
| KR20250159079A (ko) | 2019-12-20 | 2025-11-07 | 엑스더블유파마 리미티드 | 4-발레릴옥시부티르산의 합성 방법 |
| TW202139986A (zh) | 2020-02-21 | 2021-11-01 | 愛爾蘭商爵士製藥愛爾蘭有限責任公司 | 治療原發性嗜睡症之方法 |
| EP4167966A1 (en) | 2020-06-18 | 2023-04-26 | XWPharma Ltd. | Pharmaceutical granulations of water-soluble active pharmaceutical ingredients |
| EP4167971A1 (en) * | 2020-06-18 | 2023-04-26 | XWPharma Ltd. | Controlled release granulations of water-soluble active pharmaceutical ingredients |
| WO2022020621A1 (en) | 2020-07-24 | 2022-01-27 | XWPharma Ltd. | Pharmaceutical compositions and pharmacokinetics of a gamma-hydroxybutyric acid derivative |
| EP4225274A1 (en) | 2020-10-05 | 2023-08-16 | XWPharma Ltd. | Modified release compositions of a gamma-hydroxybutyric acid derivative |
| WO2022082105A2 (en) | 2020-10-16 | 2022-04-21 | Jazz Pharmaceuticals Ireland Limited | Treatment methods using ghb |
| DK4308086T3 (da) | 2021-03-19 | 2025-11-17 | Xwpharma Ltd | Farmakokinetik af formuleringer med kombineret frigivelse af et gamma-hydroxysmørsyrederivat |
| WO2023062018A1 (en) | 2021-10-11 | 2023-04-20 | Jazz Pharmaceuticals Ireland Limited | Method of administering oxybate |
| US20250073191A1 (en) | 2022-01-11 | 2025-03-06 | Jazz Pharmaceuticals Ireland Limited | Method of administering oxybate |
| CN121038779A (zh) | 2023-02-03 | 2025-11-28 | 特瑞斯制药公司 | 每晚一次的低钠羟丁酸盐组合物 |
Family Cites Families (129)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB922029A (en) | 1960-05-19 | 1963-03-27 | Equilibre Biolog L | Therapeutic composition |
| US3051619A (en) | 1960-05-19 | 1962-08-28 | Equilibre Biolog L | 4-hydroxy butyric acid therapeutic compositions and process of use for clinical sedation, hypnosis, or anaesthesia |
| DE1642902A1 (de) | 1965-09-30 | 1971-05-19 | Unilever Nv | Verfahren zur kontinuierlichen Entsaeuerung von Glyceridoelen |
| US4221778A (en) | 1979-01-08 | 1980-09-09 | Pennwalt Corporation | Prolonged release pharmaceutical preparations |
| US4374441A (en) | 1980-05-23 | 1983-02-22 | Book Covers, Inc. | Method of making a book cover and pocket element therefor |
| ZA814854B (en) | 1980-07-17 | 1982-07-28 | J Klosa | Nonhygroscopic salts of 4-hydroxybutryric acid, methods of their production and pharmaceutical preparations containing these salts |
| EP0044801B1 (de) | 1980-07-17 | 1984-02-15 | Josef Dr. Klosa | Nichthygroskopische Salze der 4-Hydroxybuttersäure, Verfahren zu ihrer Herstellung und ihre Verwendung zur Herstellung pharmazeutischer Mittel |
| CH655507B (enExample) | 1983-01-12 | 1986-04-30 | ||
| US4524217A (en) | 1984-06-08 | 1985-06-18 | Celanese Corporation | Process for producing N-acyl-hydroxy aromatic amines |
| EP0235408B1 (en) | 1984-08-06 | 1991-01-09 | The University Of Toronto Innovations Foundation | Pharmaceutical composition and treatment |
| US4687662A (en) | 1985-08-30 | 1987-08-18 | Warner-Lambert Company | Therapeutic effervescent composition |
| IE59106B1 (en) | 1985-05-31 | 1994-01-12 | Warner Lambert Co | A therapeutic effervescent composition and a method of preparing the same |
| US4738985A (en) | 1986-03-19 | 1988-04-19 | The University Of Toronto Innovations Foundations | Pharmaceutical composition and treatment |
| DE3804168A1 (de) | 1988-02-11 | 1989-08-24 | Gewerk Eisenhuette Westfalia | Planetenueberlagerungsgetriebe und ueberlagerungsantrieb fuer kettenbaender u. dgl., insbesondere fuer kettenfoerderer und kettengezogene bergbau-gewinnungsmaschinen |
| IT1217783B (it) | 1988-06-03 | 1990-03-30 | Farmaceutico Ct S R L Lab | Impiego di salo dell,acido gamma idrossi butirrico per la preparazione di composizioni farmaceutiche adatta ad essereimpiegate nella terapia dell,alcolismo e composizioni relative |
| US5294430A (en) | 1988-09-12 | 1994-03-15 | University Of Rochester | Use of dithiocarbamates to treat myelosuppression |
| US4916161A (en) | 1988-10-25 | 1990-04-10 | Bristol-Myers Squibb | Taste-masking pharmaceutical agents |
| JP2564690B2 (ja) | 1990-06-14 | 1996-12-18 | 三省製薬 株式会社 | メラニン生成抑制外用剤 |
| DE4113984C2 (de) | 1991-04-29 | 2002-05-08 | Koehler Chemie Dr Franz | Salze der 4-Hydroxy-Buttersäure |
| ES2053411T3 (es) | 1991-07-01 | 1995-05-01 | Gerhard Gergely | Sistemas efervescentes dotados de reaccion. |
| IT1271403B (it) | 1993-03-26 | 1997-05-28 | Ct Lab Farm Srl | Sali dell'acido gamma-idrossibutirrico ad attivita' ansiolitica e per il trattamento degli stati depressivi |
| FI955979L (fi) | 1993-06-14 | 1995-12-13 | Janssen Pharmaceutica Nv | Jatkuvasti vapauttava, kalvopäällysteinen astemitsoli- ja pseudoefedriinitabletti |
| IT1266565B1 (it) * | 1993-07-22 | 1997-01-09 | Ct Lab Farm Srl | Composizioni farmaceutiche a rilascio controllato a base di uno o piu' sali farmaceuticamente accettabili dell'acido gamma-idrossi-butirrico. |
| US5833599A (en) | 1993-12-13 | 1998-11-10 | Multum Information Services | Providing patient-specific drug information |
| DE4432757A1 (de) * | 1994-09-14 | 1996-03-21 | Boehringer Mannheim Gmbh | Pharmazeutische Zubereitung enthaltend Metformin und Verfahren zu deren Herstellung |
| FR2725623A1 (fr) | 1994-10-18 | 1996-04-19 | Flamel Tech Sa | Microcapsules medicamenteuses et/ou nutritionnelles pour administration per os |
| US7072840B1 (en) | 1994-10-28 | 2006-07-04 | Cybear, L.L.C. | Prescription management system |
| US5845255A (en) | 1994-10-28 | 1998-12-01 | Advanced Health Med-E-Systems Corporation | Prescription management system |
| GB9423542D0 (en) | 1994-11-22 | 1995-01-11 | Marples Brian A | Pharmaceutical compounds |
| JP4072597B2 (ja) * | 1994-12-27 | 2008-04-09 | ナムローゼ・フェンノートシャップ・オルガノン | 持続性製剤 |
| US5758095A (en) | 1995-02-24 | 1998-05-26 | Albaum; David | Interactive medication ordering system |
| US5840331A (en) | 1995-06-07 | 1998-11-24 | Arch Development Corporation | Use of γ-hydroxybutyrate for the stimulation of sleep-related secretion growth hormone and prolactin |
| US6112182A (en) | 1996-01-16 | 2000-08-29 | Healthcare Computer Corporation | Method and apparatus for integrated management of pharmaceutical and healthcare services |
| IT1283782B1 (it) | 1996-08-09 | 1998-04-30 | Ct Lab Farm Srl | Uso di ammidi dell'acido gamma-idrossibutirrico nel trattamento di tossicodipendenze,ed in particolare sell'alcolismo |
| US20080292700A1 (en) * | 1997-04-21 | 2008-11-27 | Biovail Laboratories | Controlled release formulations using intelligent polymers |
| US5990162A (en) * | 1997-08-29 | 1999-11-23 | Orphan Medical, Inc. | Method for treatment of fibromyalgia and chronic fatigue syndrome |
| US20060165606A1 (en) | 1997-09-29 | 2006-07-27 | Nektar Therapeutics | Pulmonary delivery particles comprising water insoluble or crystalline active agents |
| US6472432B1 (en) | 1997-11-17 | 2002-10-29 | Nicholas V. Perricone | Treatment of rosacea using lipoic acid |
| US6014631A (en) | 1998-04-02 | 2000-01-11 | Merck-Medco Managed Care, Llc | Computer implemented patient medication review system and process for the managed care, health care and/or pharmacy industry |
| US6322819B1 (en) | 1998-10-21 | 2001-11-27 | Shire Laboratories, Inc. | Oral pulsed dose drug delivery system |
| EP1316309A1 (en) | 1998-12-23 | 2003-06-04 | Orphan Medical Inc. | Microbiologically sound and stable solutions of gamma-hydroxybutyrate salt for the treatment of narcolepsy |
| JP4374441B2 (ja) | 1998-12-23 | 2009-12-02 | ジェイピーアイ コマーシャル，リミティド ライアビリティ カンパニー | 睡眠発作治療のための、ガンマ−ヒドロキシ酪酸塩の微生物的に安全で安定な液剤 |
| US6067524A (en) | 1999-01-07 | 2000-05-23 | Catalina Marketing International, Inc. | Method and system for automatically generating advisory information for pharmacy patients along with normally transmitted data |
| US6565872B2 (en) | 1999-02-16 | 2003-05-20 | Xiao Yu Wu | Polymeric system for drug delivery and solute separation |
| US6384020B1 (en) | 1999-07-14 | 2002-05-07 | Shire Laboratories, Inc. | Rapid immediate release oral dosage form |
| AU2001291173A1 (en) | 2000-09-22 | 2002-04-02 | Orphan Medical, Inc. | Gamma-hydroxybutyrate compositions containing carbohydrate, lipid or amino acid carriers |
| JP2004514732A (ja) | 2000-12-06 | 2004-05-20 | ファルマシア・コーポレーション | 迅速に分散する医薬組成物 |
| US8101209B2 (en) | 2001-10-09 | 2012-01-24 | Flamel Technologies | Microparticulate oral galenical form for the delayed and controlled release of pharmaceutical active principles |
| FR2830447B1 (fr) | 2001-10-09 | 2004-04-16 | Flamel Tech Sa | Forme galenique orale microparticulaire pour la liberation retardee et controlee de principes actifs pharmaceutiques |
| US20030180249A1 (en) | 2002-03-18 | 2003-09-25 | Khanna Satish Chandra | Dosage forms for hygroscopic active ingredients |
| US7985422B2 (en) * | 2002-08-05 | 2011-07-26 | Torrent Pharmaceuticals Limited | Dosage form |
| US8216609B2 (en) * | 2002-08-05 | 2012-07-10 | Torrent Pharmaceuticals Limited | Modified release composition of highly soluble drugs |
| RU2210360C1 (ru) | 2002-09-19 | 2003-08-20 | Общество С Ограниченной Ответственностью "Консорциум-Пик" | Психотропное средство |
| US7668730B2 (en) | 2002-12-17 | 2010-02-23 | JPI Commercial, LLC. | Sensitive drug distribution system and method |
| JP2006516549A (ja) | 2002-12-23 | 2006-07-06 | メルク フロスト カナダ アンド カンパニー | パーキンソン病の治療用医薬組成物及び治療方法 |
| US20050031688A1 (en) | 2003-08-04 | 2005-02-10 | Ayala William J. | Positive wakeup pharmaceutical sleep system with compatible pre-bedtime administration |
| SI1575565T1 (sl) * | 2003-08-08 | 2010-04-30 | Biovail Lab Int Srl | Tableta bupropion hidroklorida z modificiranim sprošŽŤanjem |
| WO2005013944A1 (en) | 2003-08-11 | 2005-02-17 | Merck Frosst Canada Ltd. | Flavored taste-masked pharmaceutical formulation made using a one-step coating process |
| US20050142192A1 (en) | 2003-10-15 | 2005-06-30 | Wyeth | Oral administration of [2-(8,9-dioxo-2,6-diazabicyclo[5.2.0]non-1(7)-en-2-yl)alkyl] phosphonic acid and derivatives |
| KR20070100686A (ko) | 2004-09-07 | 2007-10-11 | 오르펀 메디칼, 인크. | 개선된 ｇｈｂ 조성물 |
| US8193211B2 (en) * | 2004-09-30 | 2012-06-05 | Supernus Pharmaceuticals, Inc. | Controlled release compositions of gamma-hydroxybutyrate |
| AR051397A1 (es) | 2004-10-21 | 2007-01-10 | Novartis Ag | Composicion farmaceutica |
| CA2586975A1 (en) | 2004-11-10 | 2006-05-18 | The Trustees Of Columbia University In The City Of New York | Method for treatment of movement disorders |
| EA014249B1 (ru) | 2005-01-27 | 2010-10-29 | Алембик Лимитед | Формуляция леветирацетама длительного высвобождения |
| FR2881652B1 (fr) | 2005-02-08 | 2007-05-25 | Flamel Technologies Sa | Forme pharmaceutique orale microparticulaire anti-mesuage |
| US20080293698A1 (en) | 2005-05-16 | 2008-11-27 | Joseph Johnson | Methods and Compositions for Treating Arg |
| US7645802B2 (en) * | 2005-06-27 | 2010-01-12 | Biovail Laboratories International Srl. | Bupropion hydrobromide and therapeutic applications |
| AU2006275476A1 (en) | 2005-08-01 | 2007-02-08 | Alpharma Inc. | Alcohol resistant pharmaceutical formulations |
| PL116330U1 (en) | 2005-10-31 | 2007-04-02 | Alza Corp | Method for the reduction of alcohol provoked rapid increase in the released dose of the orally administered opioide with prolonged liberation |
| US20090317355A1 (en) | 2006-01-21 | 2009-12-24 | Abbott Gmbh & Co. Kg, | Abuse resistant melt extruded formulation having reduced alcohol interaction |
| US20070264346A1 (en) | 2006-02-16 | 2007-11-15 | Flamel Technologies | Multimicroparticulate pharmaceutical forms for oral administration |
| US8309104B2 (en) | 2006-03-02 | 2012-11-13 | Watson Pharmaceuticals, Inc. | Oral controlled release formulation for sedative and hypnotic agents |
| CN102488652B (zh) | 2006-03-16 | 2014-06-18 | 特瑞斯制药股份有限公司 | 含有药物-离子交换树脂复合物的经修饰释放的制剂 |
| US9023400B2 (en) | 2006-05-24 | 2015-05-05 | Flamel Technologies | Prolonged-release multimicroparticulate oral pharmaceutical form |
| EP2049087A2 (en) * | 2006-07-21 | 2009-04-22 | LAB International SRL | Hydrophilic abuse deterrent delivery system |
| US20080085304A1 (en) | 2006-10-10 | 2008-04-10 | Penwest Pharmaceuticals Co. | Robust sustained release formulations |
| US8394845B2 (en) | 2006-10-30 | 2013-03-12 | Hanall Biopharma Co., Ltd. | Method of using combination preparation comprising angiotensin-II-receptor blocker and HMG-CoA reductase inhibitor |
| CA2669410C (en) | 2006-11-21 | 2015-07-14 | Mcneil-Ppc, Inc. | Modified release analgesic suspensions |
| CA2930487A1 (en) | 2007-01-16 | 2008-07-24 | Egalet Ltd. | Use of i) a polyglycol and ii) an active drug substance for the preparation of a pharmaceutical composition for i)mitigating the risk of alcohol induced dose dumping and/or ii) reducing the risk of drug abuse |
| US7568822B2 (en) | 2007-03-28 | 2009-08-04 | Visteon Global Technologies, Inc. | Predictive adaptive front lighting algorithm for branching road geometry |
| US8202542B1 (en) | 2007-05-31 | 2012-06-19 | Tris Pharma | Abuse resistant opioid drug-ion exchange resin complexes having hybrid coatings |
| GB2462611A (en) * | 2008-08-12 | 2010-02-17 | Cambridge Lab | Pharmaceutical composition comprising tetrabenazine |
| US8771735B2 (en) * | 2008-11-04 | 2014-07-08 | Jazz Pharmaceuticals, Inc. | Immediate release dosage forms of sodium oxybate |
| US8778398B2 (en) | 2008-11-04 | 2014-07-15 | Jazz Pharmaceuticals, Inc. | Immediate release formulations and dosage forms of gamma-hydroxybutyrate |
| FR2938431B1 (fr) | 2008-11-14 | 2013-12-20 | Debregeas Et Associes Pharma | Nouvelle composition a base d'acide gamma-hydroxybutyrique |
| US8461197B2 (en) | 2009-04-23 | 2013-06-11 | Concert Pharmaceuticals, Inc. | 4-hydroxybutyric acid analogs |
| FR2951378B1 (fr) | 2009-10-16 | 2012-06-01 | Flamel Tech Sa | Forme pharmaceutique orale solide anti-mesusage et dotee d'un profil specifique de liberation modifiee |
| BR112012024019B1 (pt) | 2010-03-24 | 2021-10-19 | Jazz Phamaceuticals, Inc | Forma de dosagem de liberação controlada para administração oral |
| BR112012025581A2 (pt) | 2010-04-06 | 2019-09-24 | Allergan Inc | implantes de reservatório de liberação sustentada para distribuição de fármaco intracameral |
| WO2011127252A2 (en) | 2010-04-07 | 2011-10-13 | Proteus Biomedical, Inc. | Miniature ingestible device |
| EP2386289A1 (en) | 2010-04-29 | 2011-11-16 | Ipsen Pharma S.A.S. | Clay compositions |
| WO2011139271A1 (en) | 2010-05-04 | 2011-11-10 | Jazz Pharmaceuticals, Inc. | Immediate release formulations and dosage forms of gamma-hydroxybutyrate |
| WO2011140310A2 (en) | 2010-05-07 | 2011-11-10 | Microdermis Corporation | Povidone-iodine topical composition |
| CN102958930B (zh) | 2010-06-28 | 2018-04-27 | 默克专利有限公司 | 作为用于对抗癌症的激酶抑制剂的2,4-二芳基取代的[1,8]二氮杂萘化合物 |
| GB201014633D0 (en) | 2010-09-02 | 2010-10-13 | Avexxin As | Rheumatoid arthritis treatment |
| US8617602B2 (en) | 2010-09-03 | 2013-12-31 | William Wayne Howard | Immediate release compositions and methods for delivering drug formulations using weak acid ion exchange resins in abnormally high pH environments |
| PL2623498T3 (pl) | 2010-09-30 | 2016-05-31 | Toyama Chemical Co Ltd | Sól sodowa 6-fluoro-3-hydroksy-2-pirazynokarboksamidu |
| SG188662A1 (en) | 2010-09-30 | 2013-05-31 | Toyama Chemical Co Ltd | Meglumine salt of 6-fluoro-3-hydroxy-2-pyrazine carboxamide |
| US8623409B1 (en) | 2010-10-20 | 2014-01-07 | Tris Pharma Inc. | Clonidine formulation |
| US20130230587A1 (en) | 2010-11-10 | 2013-09-05 | Rubicon Research Private Limited | Sustained release compositions |
| JP2014504630A (ja) | 2011-02-02 | 2014-02-24 | アルファーマ ファーマシューティカルズ エルエルシー | オピオイドアゴニストおよび隔離されているアンタゴニストを含む医薬組成物 |
| FR2971422B1 (fr) | 2011-02-11 | 2016-05-20 | Debregeas Et Associes Pharma | Granules d'acide gamma-hydroxybutyrique |
| JP2014513046A (ja) | 2011-02-14 | 2014-05-29 | コンサート ファーマシューティカルズ インコーポレイテッド | ４−ヒドロキシ酪酸の重水素化類似体 |
| US20140072624A1 (en) | 2011-04-15 | 2014-03-13 | Threshold Pharmaceuticals, Inc. | Unit dose form for oral administration |
| US8680228B2 (en) | 2011-09-27 | 2014-03-25 | Tepha, Inc. | Controlled hydrolysis of poly-4-hydroxybutyrate and copolymers |
| US20160068463A1 (en) | 2012-11-14 | 2016-03-10 | Metabolix, Inc. | Production of salts of 4-hydroxybutyrate using biobased raw materials |
| FR2999426B1 (fr) | 2012-12-13 | 2015-01-02 | Flamel Tech Sa | Forme orale multiparticulaire a liberation immediate d'au moins un compose actif, comprenant des particules enrobees resistantes au broyage. |
| US8591922B1 (en) | 2012-12-14 | 2013-11-26 | Jazz Pharmacuticals, Inc. | Gamma-hydroxybutyrate compositions and their use for the treatment of disorders |
| US9050302B2 (en) | 2013-03-01 | 2015-06-09 | Jazz Pharmaceuticals Ireland Limited | Method of administration of gamma hydroxybutyrate with monocarboxylate transporters |
| US10751287B2 (en) | 2013-03-15 | 2020-08-25 | Purdue Pharma L.P. | Tamper resistant pharmaceutical formulations |
| US20150005334A1 (en) | 2013-03-15 | 2015-01-01 | Inspirion Delivery Technologies, Llc | Abuse deterrent compositions and methods of use |
| US9801852B2 (en) | 2013-08-30 | 2017-10-31 | Jazz Pharmaceuticals, Inc. | Devices and methods for facilitating and controlling use of a medication |
| US9770514B2 (en) | 2013-09-03 | 2017-09-26 | ExxPharma Therapeutics LLC | Tamper-resistant pharmaceutical dosage forms |
| MX373821B (es) | 2014-02-06 | 2020-03-24 | Sequential Medicine Ltd | Composición y método para ayudar a dormir. |
| EA201691582A1 (ru) | 2014-02-07 | 2017-01-30 | Оспекс Фармасьютикалз, Инк. | Новые фармацевтические препараты |
| US9962336B2 (en) | 2014-05-01 | 2018-05-08 | Sun Pharmaceutical Industries Limited | Extended release suspension compositions |
| US20160317388A1 (en) | 2014-05-01 | 2016-11-03 | Sun Pharmaceutical Industries Limited | Dual-chamber pack for extended release suspension compositions |
| EP3137060B2 (en) | 2014-05-01 | 2023-12-20 | Sun Pharmaceutical Industries Ltd | Extended release suspension compositions |
| MA41124A (fr) | 2014-12-05 | 2017-10-10 | Sun Pharmaceutical Ind Ltd | Compositions en suspension à libération prolongée à rétention gastrique |
| US10398662B1 (en) | 2015-02-18 | 2019-09-03 | Jazz Pharma Ireland Limited | GHB formulation and method for its manufacture |
| EP3288518A4 (en) | 2015-05-01 | 2018-12-12 | Sun Pharmaceutical Industries Limited | Dual-chamber pack for extended release suspension compositions |
| CA3015500A1 (en) | 2016-02-24 | 2017-08-31 | Chemapotheca, Llc | Amphetamine controlled release, prodrug, and abuse-deterrent dosage forms |
| US11000498B2 (en) | 2016-07-22 | 2021-05-11 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
| UY37341A (es) | 2016-07-22 | 2017-11-30 | Flamel Ireland Ltd | Formulaciones de gamma-hidroxibutirato de liberación modificada con farmacocinética mejorada |
| US20180263936A1 (en) | 2017-03-17 | 2018-09-20 | Jazz Pharmaceuticals Ireland Limited | Gamma-hydroxybutyrate compositions and their use for the treatment of disorders |
| CN111511355A (zh) | 2017-12-20 | 2020-08-07 | 弗拉梅爱尔兰有限公司 | 具有改善稳定性的γ-羟基丁酸盐的包装改性释放制剂 |
| MX2021005691A (es) | 2018-11-19 | 2021-07-07 | Jazz Pharmaceuticals Ireland Ltd | Formulaciones de farmacos resistentes al alcohol. |
| AU2020231916B2 (en) | 2019-03-01 | 2025-08-28 | Flamel Ireland Limited | Gamma-hydroxybutyrate compositions having improved pharmacokinetics in the fed state |
| KR20220119429A (ko) | 2019-12-24 | 2022-08-29 | 재즈 파마슈티칼즈 아일랜드 리미티드 | 감마-히드록시부티레이트(ghb) 투약 |
-
2011
- 2011-03-24 BR BR112012024019-6A patent/BR112012024019B1/pt active IP Right Grant
- 2011-03-24 US US13/071,369 patent/US20120076865A1/en not_active Abandoned
- 2011-03-24 MX MX2012011022A patent/MX377251B/es active IP Right Grant
- 2011-03-24 EP EP11760221.9A patent/EP2549987A4/en active Pending
- 2011-03-24 CN CN201180025543.3A patent/CN102917697B/zh active Active
- 2011-03-24 MX MX2020011961A patent/MX391660B/es unknown
- 2011-03-24 CA CA2794171A patent/CA2794171C/en active Active
- 2011-03-24 JP JP2013501486A patent/JP5968300B2/ja active Active
- 2011-03-24 AU AU2011232408A patent/AU2011232408B2/en not_active Ceased
- 2011-03-24 WO PCT/US2011/029802 patent/WO2011119839A1/en not_active Ceased
-
2012
- 2012-09-20 IL IL222012A patent/IL222012A/en active IP Right Grant
-
2018
- 2018-07-02 US US16/025,487 patent/US10758488B2/en active Active
-
2019
- 2019-12-12 US US16/712,260 patent/US10987310B2/en active Active
-
2020
- 2020-06-30 US US16/916,677 patent/US10813885B1/en active Active
- 2020-09-04 US US17/012,823 patent/US10959956B2/en active Active
- 2020-09-04 US US17/012,831 patent/US10966931B2/en active Active
-
2021
- 2021-04-07 US US17/224,781 patent/US11090269B1/en active Active
- 2021-07-20 US US17/380,509 patent/US11207270B2/en active Active
- 2021-12-13 US US17/549,151 patent/US20220096384A1/en not_active Abandoned
Cited By (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US12115142B2 (en) | 2016-07-22 | 2024-10-15 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
| US12115143B2 (en) | 2016-07-22 | 2024-10-15 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
| US12478604B1 (en) | 2016-07-22 | 2025-11-25 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
| US11602512B1 (en) | 2016-07-22 | 2023-03-14 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
| US11602513B1 (en) | 2016-07-22 | 2023-03-14 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
| US11766418B2 (en) | 2016-07-22 | 2023-09-26 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
| US12263151B2 (en) | 2016-07-22 | 2025-04-01 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
| US11826335B2 (en) | 2016-07-22 | 2023-11-28 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
| US11839597B2 (en) | 2016-07-22 | 2023-12-12 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
| US11896572B2 (en) | 2016-07-22 | 2024-02-13 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
| US11986451B1 (en) | 2016-07-22 | 2024-05-21 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
| US12097176B2 (en) | 2016-07-22 | 2024-09-24 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
| US12097175B2 (en) | 2016-07-22 | 2024-09-24 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
| US12109186B2 (en) | 2016-07-22 | 2024-10-08 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
| US12115144B2 (en) | 2016-07-22 | 2024-10-15 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
| US12115145B2 (en) | 2016-07-22 | 2024-10-15 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
| US11504347B1 (en) | 2016-07-22 | 2022-11-22 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
| US12263150B2 (en) | 2016-07-22 | 2025-04-01 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
| US12128021B1 (en) | 2016-07-22 | 2024-10-29 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
| US12138239B2 (en) | 2016-07-22 | 2024-11-12 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
| US12144793B2 (en) | 2016-07-22 | 2024-11-19 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
| US12257223B2 (en) | 2016-07-22 | 2025-03-25 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
| US12239625B2 (en) | 2016-07-22 | 2025-03-04 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
| US12186296B1 (en) | 2016-07-22 | 2025-01-07 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
| US12186298B2 (en) | 2016-07-22 | 2025-01-07 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
| US12226389B2 (en) | 2016-07-22 | 2025-02-18 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
| US12226388B2 (en) | 2016-07-22 | 2025-02-18 | Flamel Ireland Limited | Modified release gamma- hydroxybutyrate formulations having improved pharmacokinetics |
| US12226377B2 (en) | 2019-03-01 | 2025-02-18 | Flamel Ireland Limited | Gamma-hydroxybutyrate compositions having improved pharmacokinetics in the fed state |
| US12167992B2 (en) | 2019-03-01 | 2024-12-17 | Flamel Ireland Limited | Gamma-hydroxybutyrate compositions having improved pharmacokinetics in the fed state |
| US12167991B2 (en) | 2019-03-01 | 2024-12-17 | Flamel Ireland Limited | Gamma-hydroxybutyrate compositions having improved pharmacokinetics in the fed state |
| US11400065B2 (en) | 2019-03-01 | 2022-08-02 | Flamel Ireland Limited | Gamma-hydroxybutyrate compositions having improved pharmacokinetics in the fed state |
| US12303478B2 (en) | 2019-03-01 | 2025-05-20 | Flamel Ireland Limited | Gamma-hydroxybutyrate compositions having improved pharmacokinetics in the fed state |
| US11779557B1 (en) | 2022-02-07 | 2023-10-10 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
| US12295926B1 (en) | 2022-02-07 | 2025-05-13 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
| US11583510B1 (en) | 2022-02-07 | 2023-02-21 | Flamel Ireland Limited | Methods of administering gamma hydroxybutyrate formulations after a high-fat meal |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL222012A (en) | Controlled-release dosage forms for high-dose hygroscopic and water-soluble pharmaceuticals | |
| PT2726141T (pt) | Dispositivo para administração oral de compostos terapêuticos | |
| IL207128A0 (en) | Pharmaceutical dosage form | |
| AP2010005341A0 (en) | Solid pharmaceutical dosage form | |
| IL227383A0 (en) | Extended-release oral dosage forms containing tsucitinib | |
| PL2560624T3 (pl) | Formulacja terapeutyczna do zmniejszania skutków ubocznych leku | |
| PT2595597T (pt) | Aparelho e processo para encapsular cápsulas ou outras formas de dosagem sólida dentro de cápsulas | |
| ZA201300100B (en) | Indolizine derivatives,process for the preparation thereof and therapeutic use thereof | |
| IL225597A0 (en) | Pharmaceutical preparation, methods of treatment and its uses | |
| EP2429506A4 (en) | DOSAGE FOR COATED PHARMACEUTICAL CAPSULES | |
| IL225542A0 (en) | A mechanism for dose determination and a drug release device | |
| HUE038543T2 (hu) | MGBG-t tartalmazó szabályozott kibocsátású orális gyógyszerészeti dózis-formák | |
| ZA200903858B (en) | Pharmaceutical dosage form | |
| ZA201405797B (en) | Pharmaceutical dosage form | |
| IL219617A0 (en) | Pharmaceutical solid dosage form | |
| ZA201302012B (en) | Low dose pharmaceutical composition | |
| IL226183A0 (en) | A pharmaceutical preparation and a dosage form comprising dronedrone, and a method for their preparation | |
| EP2738176A4 (en) | WATER-SOLUBLE CAMPTOTHECIN DERIVATIVE, PHARMACEUTICAL COMPOSITION THEREFOR AND ITS USE | |
| PL2806880T3 (pl) | Kompozycja farmaceutyczna jako substancja do przeciwrefluksowego leku zobojętniającego kwas | |
| ZA201104564B (en) | Low dosage controlled release tablet | |
| ZA201209537B (en) | Pharmaceutical composition for treating drug addiction | |
| HK1181639A (zh) | 用於高剂量的水溶性和吸湿性药物的控释剂型 | |
| SI2497774T1 (sl) | Derivati dihidrooksazolobenzodiazepinona, postopki za njihovo pripravo in farmacevtski sestavki, ki te spojine vsebujejo | |
| EP2578199A4 (en) | UNIDOSE PACKAGING FOR MEDICAMENTS | |
| BR112013014963A2 (pt) | comprimido farmacêutico de liberação controlada para administração oral |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FF | Patent granted | ||
| KB | Patent renewed | ||
| KB | Patent renewed |